Review Article
Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials
Table 1
Baseline characteristics of included studies.
| Study | Year | | | | Interventions | Outcomes | Jadad score | (Ver.) | (Dil.) | (Con.) | Expt. | Ctrl. |
|
Taniyama et al. [16] | 1997 | 20 | 0 | 20 | 0.5 mg verapamil (diluted in 10 mL saline) 120 mg po follow-up study | Blank | TIMI/LVEF/WMI | 3 | Vijayalakshmi et al. [19] | 2006 | 49 | 0 | 50 | 0.5 mg verapamil | Heparinized | TIMI/MACE/TFC/WMI | 3 | Hendler et al. [20] | 2006 | 10 | 0 | 10 | 0.5 mg verapamil | Heparinized | TIMI/LVEF | 2 | Chang et al. [21] | 2010 | 29 | 0 | 35 | 100–400 g verapamil | Nitroglycerin | CTFC | 2 | Huang et al. [22] | 2012 | 34 | 34 | 34 | 200 g verapamil (max 1 mg) 400 g diltiazem (max 1 mg) | Nitroglycerin (max 1 mg) | TIMI/CTFC/LVEF/MACE | 3 | Li et al. [23] | 2012 | 0 | 40 | 39 | Diltiazem 90 mg bid/6 months | Placebo | TIMI/CTFC/LVEF/MACE | 6 | Ozdogru et al. [24] | 2013 | 0 | 30 | 30 | 5 mg diltiazem | Nitroglycerin | CTFC/HR/BP | 2 | Akturk et al. [25] | 2014 | 15 | 0 | 15 | Verapamil | Placebo | CTFC/LEVF | 2 | Overall | | 157 | 104 | 233 | | | | |
|
|